For over 55 years, bioMérieux has been a global leader in the development and production of in vitro diagnostic solutions (systems, reagents, software, and services) for private and hospital laboratories, mainly for the diagnosis of infectious diseases and for industrial microbiology requirements in food, pharma, and cosmetic production. Their € 2.7 billion in sales comes from over 160 countries and is supported by 12,000 employees and 18 production and R&D sites.
bioMérieux's strategy to combat COVID-19 illustrates its commitment to serve public health. The company has received Emergency Use Authorization by the U.S. Food and Drug Administration of its BIOFIRE® COVID-19 test for use in CLIA moderate and high complexity clinical laboratories. bioMérieux expects to have maximum production capability within a few weeks to address the needs of the thousands of labs and healthcare professionals using one of the nearly 11000 BIOFIRE® systems worldwide.